Frustrated Eli Lilly may have to settle for a lonely last-place finish in the blockbuster CDK 4/6 race
A frustrated Eli Lilly will have to wait patiently for its closely-watched Phase III study of the CDK 4/6 breast cancer drug abemaciclib to wrap up next year before it gets the final read out on its effect on survival rates. The pharma giant reported that the pivotal trial will have to continue “as the interim efficacy criteria were not met.”
Final results are now expected sometime in the first half of 2017, which could delay a launch into 2018.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.